The Emerging Power of Mass Spectrometry in Oncology

The article discusses the potential of mass spectrometry (MS) in oncology, specifically for liquid biopsy-based early detection of cancer. As the incidence of newly diagnosed cancer cases is projected to rise over the next decade, there is an urgent need for technological advancements that enable early detection and improve patient outcomes.

Liquid biopsy, a minimally invasive blood-based technology that detects tumor-derived biomarkers, holds promise in this regard. Many liquid biopsy assays are being developed or are in early stages of commercial availability, designed to detect mutations, methylation patterns, and fragmentation patterns in circulating tumor DNA (ctDNA) using next-generation sequencing (NGS)-based technologies.

However, limitations such as complexity, cost, and unproven performance for early-stage cancer detection remain. MS-based omics approaches, including proteomics, lipidomics, and metabolomics, offer a powerful alternative to these limitations. MS-based proteomics has matured into a robust, high-throughput platform that can quantify thousands of proteins and map the proteome across multiple cancer types.

Proteins serve as the critical link between the genotype and the phenotype of a disease, making them the key to understanding cancer progression and metastasis. The article suggests that MS has the potential to deliver proteomics-based profiles for oncology-based applications, providing a more accurate and efficient means of early cancer detection.

Brief written by urgent.news from GEN Biotechnology's own syndicated text. Machine-written — may contain errors; check the original before relying on it.